Cancer Self-Defense: An Immune Stealth

Abstract The hurdles in realizing immunotherapy success for cure stem from the fact that cancer patients are either refractory to immune response and/or develop resistance. Here, we propose that these phenomena are due, in part, to the deployment of a 'decoy flare' i.e., release or secretion of anomalous cancer-associated antigens. The cancer secretome, that resembles the parent cell make up, is composed of soluble macromolecules (proteins, glycans, lipids, DNAs, RNAs etc.) and insoluble vesicles (exosomes), thus hindering cancer detection/recognition by immunotherapeutic agents resulting in a 'cancer-stealth' effect. A clinical evaluation of tumor-derived secretome and specific autoantibodies may change the therapeutic landscape

http://ift.tt/2ixnDCO